BCIQ Profiles

Company Profile Report
0709 Celldex EMB 6.01pm ET
BioCentury & Getty Images

Product Development

Comeback kid: Celldex gets latest lift from acquired urticaria program

Celldex’s KIT inhibitor is slated to enter Phase II testing next half. 

Celldex’s KIT inhibitor is slated to enter Phase II testing next half. 

Jul 9, 2021 | 10:03 PM GMT

Celldex’s latest revival is largely thanks to a 2016 acquisition that gave the company a KIT inhibitor that has now produced

Read the full 681 word article

How to gain access

Continue reading with a
two-week free trial.